skip page navigationOregon State University

Faculty

Sharon K. Krueger, Ph.D.

Research Assistant Professor, Linus Pauling Institute

Office: 459 Linus Pauling Science Center

Telephone: (541) 737-9322

Fax: (541) 737-5077

Email Address: sharon.krueger@oregonstate.edu

Mailing/Express Delivery Address:
Sharon K. Krueger, Ph.D.
Linus Pauling Institute
Oregon State University
307 Linus Pauling Science Center
Corvallis, OR 97331


Research Interests

The flavin-containing monooxygenases (FMOs) and cytochrome P450s (CYPs) are enzymes that oxygenate many of the drugs and chemicals that we ingest, inhale, or absorb. I am interested in the role these enzymes play in modulating disease and the impact of genetic variants on metabolism, especially in cancer and tuberculosis. Sulindac is an anti-inflammatory drug used to treat individuals with familial adenomatous polyposis (FAP), an inherited disorder characterized by colorectal cancer. FMO3 oxygenates sulindac sulfide, leading to its increased excretion. Studies have shown that among individuals with FAP, those with FMO3 polymorphisms (genetic variations) that have a reduced capacity to oxygenate and excrete sulindac have a reduced polyp and tumor burden. A human study has demonstrated that dietary consumption of Brussels sprouts decreases conversion of trimethylamine to trimethylamine N-oxide, another reaction catalyzed by FMO3. We are investigating the hypothesis that consumption of Brussels sprouts will reduce and delay sulindac oxygenation. If this is correct, dietary regulation of FMO3 could become a strategy for enhancing and prolonging the efficacy of sulindac and reducing the impact of FAP.

Whereas FMO3 is the predominant FMO in human liver, FMO2 is the dominant isoform in lung. However, only some individuals of African or Hispanic/Latino descent produce active protein; all other populations have a polymorphism for FMO2, rendering them with little capacity for metabolism of FMO substrates in the lung. Several classes of anti-tuberculosis drugs require activation by FMOs for bactericidal activity. Mycobacteria (causative agents for TB and leprosy) have their own FMO that activates these drugs. We have hypothesized that people with active FMO2 who have TB and are treated with these drugs will have a different drug response (toxicity and efficacy) from people without active FMO2. We are testing this hypothesis using mice with and without FMO2, and if correct, physicians may have a strategy to tailor drug therapy for TB on the basis of FMO2 polymorphism.


Education

1983 B.S., Horticulture, University of Wisconsin-Madison
1986 M.S., Plant Breeding and Plant Genetics, University of Wisconsin-Madison
1990 Ph.D., Plant Breeding, Oregon State University

Professional Experience

1990-1992 Faculty Research Assistant, Department of Botany and Plant Pathology, Oregon State University
1992-1993 Research Associate, Department of Fisheries and Wildlife, Oregon State University
1994 Instructor, Department of Zoology, Oregon State University
1993-2006 Research Associate, Department of Environmental and Molecular Toxicology, Oregon State University
2006-present Research Assistant Professor, Linus Pauling Institute, Oregon State University

Memberships

American Association for the Advancement of Science
International Society for the Study of Xenobiotics
Pacific Northwest Association of Toxicologists
Society of Toxicology


Current Funding

NIH/NHLBI, R01 HL38650 (Co-I), Flavin-Containing Monooxygenase in Lung (2005-2008)


Recent Publications

Siddens LK, Krueger SK, Henderson MC, Williams DE. (2014) Mammalian flavin-containing monooxygenase (FMO) as a source of hydrogen peroxide. Biochem Pharmacol [Epub ahead of print].

Larkin A, Siddens LK, Krueger SK, Tilton SC, Waters KM, Williams DE, Baird WM. (2013) Application of a fuzzy neural network model in predicting polycyclic aromatic hydrocarbon-mediated perturbations of the Cyp1b1 transcriptional regulatory network in mouse skin. Toxicol Appl Pharmacol 267:192-199.

Palmer AL, Leykam VL, Larkin A, Krueger SK, Phillips IR, Shephard EA, Williams DE. (2012) Metabolism and pharmacokinetics of the anti-tuberculosis drug ethionamide in a flavin-containing monooxygenase null mouse. Pharmaceuticals (Basel) 5:1147-1159.

Siddens LK, Larkin A, Krueger SK, Bradfield CA, Waters KM, Tilton SC, Pereira CB, Löhr CV, Arlt VM, Phillips DH, Williams DE, Baird WM. (2012) Polycyclic aromatic hydrocarbons as skin carcinogens: comparison of benzo[a]pyrene, dibenzo[def,p]chrysene and three environmental mixtures in the FVB/N mouse. Toxicol Appl Pharmacol 264:377-386.

Celius T, Pansoy A, Matthews J, Okey AB, Henderson MC, Krueger SK, Williams DE (2010) Flavin-containing monooxygenase-3: induction by 3-methylcholanthrene and complex regulation by xenobiotic chemicals in hepatoma cells and mouse liver. Toxicol Appl Pharmacol 247:60-69.

Krueger SK, Henderson MC, Siddens LK, VanDyke JE, Benninghoff AD, Karplus PA, Furnes B, Schlenk D, Williams DE (2009) Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K. Drug Metab Dispos 37:1785-1791.